Abbott will be opening its largest nutrition product manufacturing facility in Singapore, to meet increasing regional demand for its nutritional products, including Similac. This represents the company's single largest investment in Asia and its growing commitment to the region.

Abbott Manufacturing Singapore is a center of excellence, offering world-class levels of safety, process control and cleanliness throughout the manufacturing and distribution process.  The plant employs approximately 300 people, 50 of whom are solely devoted to quality assurance.  

Additionally, Abbott announced its new Asia-Pacific Nutrition Science Research and Development Center in Singapore, where its scientists will focus on clinical trials and development of nutritional products tailored to Asian dietary needs.  This center of excellence complements Abbott's new pharmaceutical research and development facility, opened last month in Singapore.

Abbott has expanded its presence in the country over the past few years with the launch of several key products, including HUMIRA® and the XIENCE V™ drug-eluting stent.  Singapore is also home to the regional headquarters for several Abbott businesses, including nutrition, pharmaceuticals and diagnostics.